The effective control of a bleeding injury using a medical adhesive containing batroxobin

Kyung Eun You, Min Ah Koo, Dae Hyung Lee, Byeong Ju Kwon, Mi Hee Lee, Suong Hyu Hyon, Young Seomun, Jong Tak Kim, Jong Chul Park

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Many types of hemostatic agents have been studied for the effective control of bleeding. In this study, a powdery medical adhesive composed of aldehyded dextran and ε-poly (L-lysine) was used with the recombinant batroxobin. Batroxobin is a venomous component from the snake Bothrops atrox moojeni and catalyzes fibrinogen conversion to form soluble fibrin clots. This research aims to examine the performance of the batroxobin-containing adhesive for hemostasis, and evaluate its potential as a novel hemostatic adhesive. The fibrinogen conversion ability of batroxobin was evaluated by a fibrinogen clotting assay and a whole blood clotting assay. Both experiments demonstrated the effectiveness of the batroxobin-containing adhesive for blood clot formation. Animal experiments were also conducted. After a pricking wound was made in an ICR (imprinting control region) mouse liver, the adhesive and various concentrations of batroxobin were applied. The total amount of blood loss was reduced with increasing concentrations of batroxobin. For excessive bleeding conditions, the femoral artery wound model of SD (Sprague-Dawley) rats was adopted. With higher concentrations of batroxobin, hemostasis was more rapidly achieved. Histological analysis of the liver model also supports the hemostatic effects through fibrin clot formation. In conclusion, batroxobin and medical adhesive effectively facilitate blood coagulation, and could be developed for clinical use.

Original languageEnglish
Article number025002
JournalBiomedical Materials (Bristol)
Volume9
Issue number2
DOIs
Publication statusPublished - 2014 Apr

Fingerprint

Batroxobin
Adhesives
Hemorrhage
Wounds and Injuries
Blood
Hemostatics
Liver
Fibrinogen
Assays
Blood Coagulation
Hemostasis
Fibrin
Dextran
Coagulation
Bothrops
Rats
Animals
Snakes
Experiments
Femoral Artery

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

You, Kyung Eun ; Koo, Min Ah ; Lee, Dae Hyung ; Kwon, Byeong Ju ; Lee, Mi Hee ; Hyon, Suong Hyu ; Seomun, Young ; Kim, Jong Tak ; Park, Jong Chul. / The effective control of a bleeding injury using a medical adhesive containing batroxobin. In: Biomedical Materials (Bristol). 2014 ; Vol. 9, No. 2.
@article{a409c09c6de4412fb234e4562c0c2f42,
title = "The effective control of a bleeding injury using a medical adhesive containing batroxobin",
abstract = "Many types of hemostatic agents have been studied for the effective control of bleeding. In this study, a powdery medical adhesive composed of aldehyded dextran and ε-poly (L-lysine) was used with the recombinant batroxobin. Batroxobin is a venomous component from the snake Bothrops atrox moojeni and catalyzes fibrinogen conversion to form soluble fibrin clots. This research aims to examine the performance of the batroxobin-containing adhesive for hemostasis, and evaluate its potential as a novel hemostatic adhesive. The fibrinogen conversion ability of batroxobin was evaluated by a fibrinogen clotting assay and a whole blood clotting assay. Both experiments demonstrated the effectiveness of the batroxobin-containing adhesive for blood clot formation. Animal experiments were also conducted. After a pricking wound was made in an ICR (imprinting control region) mouse liver, the adhesive and various concentrations of batroxobin were applied. The total amount of blood loss was reduced with increasing concentrations of batroxobin. For excessive bleeding conditions, the femoral artery wound model of SD (Sprague-Dawley) rats was adopted. With higher concentrations of batroxobin, hemostasis was more rapidly achieved. Histological analysis of the liver model also supports the hemostatic effects through fibrin clot formation. In conclusion, batroxobin and medical adhesive effectively facilitate blood coagulation, and could be developed for clinical use.",
author = "You, {Kyung Eun} and Koo, {Min Ah} and Lee, {Dae Hyung} and Kwon, {Byeong Ju} and Lee, {Mi Hee} and Hyon, {Suong Hyu} and Young Seomun and Kim, {Jong Tak} and Park, {Jong Chul}",
year = "2014",
month = "4",
doi = "10.1088/1748-6041/9/2/025002",
language = "English",
volume = "9",
journal = "Biomedical Materials (Bristol)",
issn = "1748-6041",
publisher = "IOP Publishing Ltd.",
number = "2",

}

The effective control of a bleeding injury using a medical adhesive containing batroxobin. / You, Kyung Eun; Koo, Min Ah; Lee, Dae Hyung; Kwon, Byeong Ju; Lee, Mi Hee; Hyon, Suong Hyu; Seomun, Young; Kim, Jong Tak; Park, Jong Chul.

In: Biomedical Materials (Bristol), Vol. 9, No. 2, 025002, 04.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effective control of a bleeding injury using a medical adhesive containing batroxobin

AU - You, Kyung Eun

AU - Koo, Min Ah

AU - Lee, Dae Hyung

AU - Kwon, Byeong Ju

AU - Lee, Mi Hee

AU - Hyon, Suong Hyu

AU - Seomun, Young

AU - Kim, Jong Tak

AU - Park, Jong Chul

PY - 2014/4

Y1 - 2014/4

N2 - Many types of hemostatic agents have been studied for the effective control of bleeding. In this study, a powdery medical adhesive composed of aldehyded dextran and ε-poly (L-lysine) was used with the recombinant batroxobin. Batroxobin is a venomous component from the snake Bothrops atrox moojeni and catalyzes fibrinogen conversion to form soluble fibrin clots. This research aims to examine the performance of the batroxobin-containing adhesive for hemostasis, and evaluate its potential as a novel hemostatic adhesive. The fibrinogen conversion ability of batroxobin was evaluated by a fibrinogen clotting assay and a whole blood clotting assay. Both experiments demonstrated the effectiveness of the batroxobin-containing adhesive for blood clot formation. Animal experiments were also conducted. After a pricking wound was made in an ICR (imprinting control region) mouse liver, the adhesive and various concentrations of batroxobin were applied. The total amount of blood loss was reduced with increasing concentrations of batroxobin. For excessive bleeding conditions, the femoral artery wound model of SD (Sprague-Dawley) rats was adopted. With higher concentrations of batroxobin, hemostasis was more rapidly achieved. Histological analysis of the liver model also supports the hemostatic effects through fibrin clot formation. In conclusion, batroxobin and medical adhesive effectively facilitate blood coagulation, and could be developed for clinical use.

AB - Many types of hemostatic agents have been studied for the effective control of bleeding. In this study, a powdery medical adhesive composed of aldehyded dextran and ε-poly (L-lysine) was used with the recombinant batroxobin. Batroxobin is a venomous component from the snake Bothrops atrox moojeni and catalyzes fibrinogen conversion to form soluble fibrin clots. This research aims to examine the performance of the batroxobin-containing adhesive for hemostasis, and evaluate its potential as a novel hemostatic adhesive. The fibrinogen conversion ability of batroxobin was evaluated by a fibrinogen clotting assay and a whole blood clotting assay. Both experiments demonstrated the effectiveness of the batroxobin-containing adhesive for blood clot formation. Animal experiments were also conducted. After a pricking wound was made in an ICR (imprinting control region) mouse liver, the adhesive and various concentrations of batroxobin were applied. The total amount of blood loss was reduced with increasing concentrations of batroxobin. For excessive bleeding conditions, the femoral artery wound model of SD (Sprague-Dawley) rats was adopted. With higher concentrations of batroxobin, hemostasis was more rapidly achieved. Histological analysis of the liver model also supports the hemostatic effects through fibrin clot formation. In conclusion, batroxobin and medical adhesive effectively facilitate blood coagulation, and could be developed for clinical use.

UR - http://www.scopus.com/inward/record.url?scp=84896898374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896898374&partnerID=8YFLogxK

U2 - 10.1088/1748-6041/9/2/025002

DO - 10.1088/1748-6041/9/2/025002

M3 - Article

C2 - 24487019

AN - SCOPUS:84896898374

VL - 9

JO - Biomedical Materials (Bristol)

JF - Biomedical Materials (Bristol)

SN - 1748-6041

IS - 2

M1 - 025002

ER -